Skip to main content
. 2024 Jun;24(6):594–601. doi: 10.1016/S1473-3099(23)00818-6

Table 1.

Baseline demographic and clinical characteristics at baseline in the intention-to-treat population

BCG group (n=996) Placebo group (n=989)
Sex
Female 723 (72·6%) 752 (76·0%)
Male 273 (27·4%) 237 (24·0%)
Age (years) 39·0 (31·0–47·0) 40·0 (32·0–48·0)
Coexisting condition 223 (22·4%) 228 (23·1%)
Diabetes 35 (3·5%) 40 (4·0%)
Chronic respiratory disease 51 (5·1%) 42 (4·2%)
Cardiovascular disease or hypertension 137 (13·8%) 146 (14·8%)
Any alcohol use 479 (48·1%) 459 (46·4%)
Smoker 96 (9·6%) 106 (10·7%)
Previous BCG vaccination status
No 37 (3·7%) 40 (4·0%)
1–5 years ago 7 (0·7%) 11 (1·1%)
>5 years ago 952 (95·6%) 938 (94·8%)
Previous positive tuberculin skin test
No 948 (95·2%) 918 (92·8%)
Not sure 23 (2·3%) 31 (3·1%)
Yes 25 (2·5%) 40 (4·0%)
Occupation
Allied health 123 (12·3%) 125 (12·6%)
Administrative or clerical 84 (8·4%) 89 (9·0%)
Physician 36 (3·6%) 36 (3·6%)
Nurse or midwife 97 (9·7%) 103 (10·4%)
Other role 518 (52·0%) 527 (53·3%)
Patient service assistant or hospital maintenance 138 (13·9%) 109 (11·0%)
Site
Campo Grande 546 (54·8%) 545 (55·1%)
Rio de Janeiro 291 (29·2%) 293 (29·6%)
Manaus 159 (16·0%) 151 (15·3%)

Data are n (%) or median (IQR).